![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAM213B |
Gene summary for FAM213B |
![]() |
Gene information | Species | Human | Gene symbol | FAM213B | Gene ID | 127281 |
Gene name | peroxiredoxin like 2B | |
Gene Alias | C1orf93 | |
Cytomap | 1p36.32 | |
Gene Type | protein-coding | GO ID | GO:0001516 | UniProtAcc | A0A0A0MT35 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
127281 | FAM213B | S028 | Human | Liver | HCC | 6.62e-21 | 5.50e-01 | 0.2503 |
127281 | FAM213B | S029 | Human | Liver | HCC | 6.49e-11 | 4.91e-01 | 0.2581 |
127281 | FAM213B | C04 | Human | Oral cavity | OSCC | 1.42e-07 | 4.00e-01 | 0.2633 |
127281 | FAM213B | C21 | Human | Oral cavity | OSCC | 5.94e-24 | 8.00e-01 | 0.2678 |
127281 | FAM213B | C30 | Human | Oral cavity | OSCC | 8.50e-14 | 5.87e-01 | 0.3055 |
127281 | FAM213B | C43 | Human | Oral cavity | OSCC | 1.21e-27 | 5.61e-01 | 0.1704 |
127281 | FAM213B | C46 | Human | Oral cavity | OSCC | 3.08e-02 | 1.34e-01 | 0.1673 |
127281 | FAM213B | C57 | Human | Oral cavity | OSCC | 1.78e-02 | 1.61e-01 | 0.1679 |
127281 | FAM213B | C08 | Human | Oral cavity | OSCC | 5.50e-08 | 2.35e-01 | 0.1919 |
127281 | FAM213B | LN46 | Human | Oral cavity | OSCC | 1.64e-04 | 1.85e-01 | 0.1666 |
127281 | FAM213B | SYSMH2 | Human | Oral cavity | OSCC | 8.86e-03 | 1.57e-01 | 0.2326 |
127281 | FAM213B | SYSMH3 | Human | Oral cavity | OSCC | 1.08e-06 | 2.17e-01 | 0.2442 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM213B | SNV | Missense_Mutation | rs200164303 | c.631G>A | p.Val211Ile | p.V211I | protein_coding | tolerated(0.55) | benign(0.038) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
FAM213B | SNV | Missense_Mutation | novel | c.85N>A | p.Ala29Thr | p.A29T | protein_coding | deleterious_low_confidence(0.01) | benign(0.376) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FAM213B | SNV | Missense_Mutation | c.643C>A | p.Pro215Thr | p.P215T | protein_coding | deleterious(0.03) | probably_damaging(0.967) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
FAM213B | SNV | Missense_Mutation | novel | c.671T>C | p.Ile224Thr | p.I224T | protein_coding | deleterious(0) | possibly_damaging(0.713) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
FAM213B | SNV | Missense_Mutation | rs748716490 | c.512G>A | p.Arg171His | p.R171H | protein_coding | deleterious(0.03) | benign(0.045) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FAM213B | SNV | Missense_Mutation | c.643N>G | p.Pro215Ala | p.P215A | protein_coding | tolerated(0.24) | benign(0.365) | TCGA-DD-A1EL-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | ||
FAM213B | SNV | Missense_Mutation | c.603N>C | p.Lys201Asn | p.K201N | protein_coding | deleterious(0.01) | probably_damaging(0.913) | TCGA-85-6560-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD | ||
FAM213B | SNV | Missense_Mutation | rs757946334 | c.580G>A | p.Gly194Arg | p.G194R | protein_coding | tolerated(0.07) | possibly_damaging(0.905) | TCGA-XC-AA0X-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FAM213B | SNV | Missense_Mutation | c.601N>C | p.Lys201Gln | p.K201Q | protein_coding | tolerated(0.06) | possibly_damaging(0.885) | TCGA-BR-8676-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |